{
    "root": "2f2686e7-30b2-2b0a-e063-6394a90a5a29",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lamotrigine",
    "value": "20250227",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "LAMOTRIGINE",
            "code": "U3H27498KS"
        }
    ],
    "indications": "lamotrigine tablets indicated : epilepsy—adjunctive therapy patients aged 2 years older : partial-onset seizures . primary generalized tonic-clonic seizures . generalized seizures lennox-gastaut syndrome . ( 1.1 ) epilepsy—monotherapy patients aged 16 years older : conversion monotherapy patients partial-onset seizures receiving treatment carbamazepine , phenytoin , phenobarbital , primidone , valproate single antiepileptic . ( 1.1 ) bipolar disorder : maintenance treatment bipolar disorder delay time occurrence mood episodes patients treated acute mood episodes standard therapy . ( 1.2 ) limitations : treatment acute manic mixed episodes recommended . effectiveness lamotrigine tablets acute treatment mood episodes established .",
    "contraindications": "dosing based concomitant medications , indication , patient age . ( 2.1 , 2.2 , 2.3 , 2.4 ) avoid increased risk rash , recommended initial dose subsequent dose escalations exceeded . ( 2.1 ) restart lamotrigine tablets patients discontinued due rash unless potential benefits clearly outweigh risks . ( 2.1 , 5.1 ) adjustments maintenance doses necessary patients starting stopping estrogen-containing oral contraceptives . ( 2.1 , 5.9 ) discontinuation : taper period least 2 weeks ( approximately 50 % dose reduction per week ) . ( 2.1 , 5.10 ) epilepsy : adjunctive therapy—see table 1 patients older 12 years tables 2 3 patients aged 2 12 years . ( 2.2 ) conversion monotherapy—see table 4 . ( 2.3 ) bipolar disorder : tables 5 6 . ( 2.4 )",
    "warningsAndPrecautions": "lamotrigine tablets usp , 25 mg white , caplet shaped , biconvex tablets ' u ' debossed either side break line one side '111 ' debossed side . ndc : 70518-1908-00 ndc : 70518-1908-01 ndc : 70518-1908-02 ndc : 70518-1908-03 ndc : 70518-1908-04 packaging : 30 1 blister pack packaging : 30 1 blister pack packaging : 30 1 blister pack packaging : 180 1 bottle plastic packaging : 30 1 bottle plastic store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] dry place . dispense tight , light-resistant container defined usp . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hypersensitivity ingredients . ( boxed warning , 4 )",
    "indications_original": "Lamotrigine tablets are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic      seizures. generalized seizures of Lennox-Gastaut      syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established.",
    "contraindications_original": "Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. ( 2.1 ) Do not restart lamotrigine tablets in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. ( 2.1 , 5.9 ) Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). ( 2.1 , 5.10 ) Epilepsy : Adjunctive therapy—See Table 1 for      patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12      years. ( 2.2 ) Conversion to monotherapy—See Table      4. ( 2.3 ) Bipolar disorder : See Tables 5 and 6. ( 2.4 )",
    "warningsAndPrecautions_original": "Lamotrigine Tablets USP, 25 mg\n                  White, caplet shaped, biconvex tablets with 'U' debossed on either side of break line on one side and '111' debossed on other side.\n                  NDC: 70518-1908-00\n                  NDC: 70518-1908-01\n                  NDC: 70518-1908-02\n                  NDC: 70518-1908-03\n                  NDC: 70518-1908-04\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 180 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in a dry place.\n                  Dispense in tight, light-resistant container as defined in the USP.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hypersensitivity to the drug or its ingredients. ( Boxed Warning , 4 )"
}